NSCLC: sotorasib first therapy approved against the KRAS G12C mutation

Non-small-cell lung cancer (NSCLC) represents 84% of all cases of lung cancer diagnoses and accounts for around 400,000 new cases each year in Europe.

13-15% of patients with NSCLC harbour the KRAS G12C mutation. For these patients treatment options are limited and with suboptimal outcomes: progression-free survival is approximately 4 months following second-line treatment.

Sotorasib is the first drug approved by the European Commission for the treatment of patients with advanced NSCLC and KRAS G12C mutation, who have progressed after at least one prior line of systemic therapy. The KRAS G12C inhibitor demonstrated an objective response rate of 37.1%, a median duration of response of 11.1 months and a manageable safety profile.

Myriapod^® NGS Cancer panel DNA and EasyPGX^® ready KRAS are Diatech Pharmacogenetics solutions for oncological molecular analysis that ensure maximum sensitivity and standardization for the detection of the KRAS G12C mutation and the selection of NSCLC patients candidates for therapy with sotorasib.